During the past couple of years, COVID-19 has been probably the most popular theme for discussions. Unfortunately, despite actively conducting research, no sufficiently effective therapy has been found to protect patients at risk from acute respiratory failure due to SARS-CoV-2 virus infection and reduce mortality. Therefore, the need to find new therapeutic strategies is vital.
Exolitus team, together with three academic partners, has challenged themselves to develop an industrial hemp exosome-based technology preventing COVID-19 and relieving inflammatory symptoms.
We are happy that this initiative got support from EU Regional Funds via the Research Council of Lithuania (Grant Agreement No. 01.2.2-LMT-K-718-05-0039). We believe that our joint efforts will help prevent severe acute respiratory failure caused by COVID-19 at both national and global levels.
Funded by the European Regional Development Fund as part of the European Union’s response to the COVID-19 pandemic.
